Peer-reviewed veterinary case report
PDGFR-beta and VEGFR2 protein in dog bladder cancer cells
By Walters, L et al.·Published in Veterinary and comparative oncology·2018·Department of Small Animal Clinical Sciences·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Expression of receptor tyrosine kinase targets PDGFR-β, VEGFR2 and KIT in canine transitional cell carcinoma.
- Species:
- dog
Plain-English summary
A dog with transitional cell carcinoma (TCC), a common type of bladder cancer, was studied to see how well certain proteins related to growth and cell function were expressed in the tumor. Researchers found that a significant number of TCC samples showed a specific protein (PDGFR-β) compared to normal bladder tissue, while all tumor samples had another protein (VEGFR2). This suggests that the cancer may respond to a treatment called toceranib phosphate, which has been used to help manage TCC. Further studies are needed to see how effective this treatment is for dogs with this condition.
People also search for: dog bladder cancer treatment · transitional cell carcinoma in dogs · toceranib phosphate for dog cancer
Abstract
Transitional cell carcinoma (TCC) is the most common neoplasia of the canine urinary tract. It tends to be locally invasive and has a moderate metastatic rate. Receptor tyrosine kinases (RTKs) play an important role in promoting cell growth, differentiation and regulation of cell function. RTK inhibitor toceranib phosphate has been used anecdotally to treat TCC. The goal of this study was to evaluate archived normal urinary bladder, TCC and cystitis bladder samples for expression of toceranib phosphate targets: VEGFR2, PDGFR-β and stem cell factor receptor (KIT). A significant number of TCC samples expressed PDGFR-β compared with cystitis and normal bladder samples (P<.0001). While all the tumour samples stained positively for VEGFR2, there was no significant difference between tumour, cystitis and normal bladder samples in intensity scores or staining distribution. Minimal positive staining for KIT was noted in the tumour samples. Based on this proof of target study, further investigation is warranted to determine clinical response of TCC to toceranib phosphate.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/28884928/